In a report published Wednesday, Jefferies reiterated its Buy rating on Danaher Corporation DHR, and raised its price target from $66.00 to $70.00.
Jefferies noted, “The merits of DHR's portfolio re-positioning efforts were clearly on display in 4Q12 as core revenue growth vitality in its Life Sciences & Diagnostics unit (+7%) helped mitigate the effects of tepid trends in its industrial-oriented franchises. We are revising our 2013 EPS forecast to $3.48 (from $3.50) to account for the Apex Tool JV divestiture in 1Q13 (-$0.02). Our PT moves to $70 (from $66) on higher cash flow forecasts.”
Danaher Corporation closed on Tuesday at $61.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in